Long-term results of fluocinolone acetonide intravitreal implant in Behçet intractable posterior uveitis

Canadian Journal of Ophthalmology

Volumn 49, Issue 3, 2014, Pages 273-278

  Oh, Eun Kyu ^a   Lee, Eun Kyoung ^a   Yu, Hyeong Gon ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUOCINOLONE ACETONIDE; VALGANCICLOVIR; GLUCOCORTICOID;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CATARACT EXTRACTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS ENDOTHELITIS; DRUG SAFETY; EYE INFECTION; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INFLAMMATION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MALE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; DRUG EFFECT; DRUG IMPLANT; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; VITREOUS BODY;

ADOLESCENT; ADULT; BEHCET SYNDROME; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS, POSTERIOR; VISUAL ACUITY; VITREOUS BODY;

EID: 84907559041     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2014.03.004     Document Type: Article

References (20)

1. Castellarin A, Pieramici DJ. Anterior segment complications following periocular and intraocular injections. Ophthalmol Clin North Am. 2004; 17: 583-90.
2. Carnahan MC, Goldstein DA. Ocular complications of topical, periocular and systemic corticosteroids. Curr Opin Ophthalmol. 2000; 11: 478-83.
3. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr Risks of intravitreous injection: a comprehensive review. Retina. 2004; 24: 676-98.
4. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003; 136: 791-6.
5. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130: 492-513.
6. + T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis. Invest Ophthalmol Vis Sci. 2005; 46: 2458-64.
7. + T cells are cytotoxic effectors in patients with active Behçet's uveitis. J Immunol. 2005; 175: 6133-42.
8. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000; 41: 3569-75.
9. Yousuf K, Allison RL, Nisha RA. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2009; 17: 431-3.
10. Rajeev KS, Paul AG. Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. Ocul Immunol Inflamm. 2008; 16: 103-5.
11. Vinit BM, Karen MG, Debra AG, et al. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology. 2009; 116: 552-7.
12. Gold DH Ocular manifestations of connective tissue (collagen) diseases. In: Tasman W, Jaeger AE, eds. Duane's Clinical Ophthalmology. Philadelphia: J.B. Lippincott 1989: 17-9
13. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140: 509-16.
14. Unchul P, Sangjin K, Hyeonggon Y. Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behçet uveitis. Ocul. Immunol. Inflamm. 2011; 19: 282-3.
15. Davatchi F, Shahram F, Chams-Davatchi C, et al. How to deal with Behcet's disease in the daily practice. Int J Rheum Dis. 2010; 13: 105-16.
16. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha-2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008; 146: 837-44.
17. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology. 2007; 46: 1161-4.
18. Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007; 1110: 474-84.
19. Ahn JK, Chung H, Yu HG. Vitrectomy for persistent panuveitis in Behcet's disease. Ocul Immunol Inflamm. 2005; 13: 447-53.
20. Tugal-Tutkun I, Araz B, Cagatay A. CMV retinitis after intravitreal triamcinolone acetonide injection in a patient with Behcet's uveitis. Int Ophthalmol. 2010; 30: 591-3.